{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"12.8","value":"8.3"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"9.0","value":"6.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"MEDIAN","populationDescription":"ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.","reportingStatus":"POSTED","timeFrame":"24.6 months","title":"Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR","type":"SECONDARY","unitOfMeasure":"months"}